About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, announced today that it has been notified that the Chief Executive Officer, Gary S. Jacob, has purchased 10,000 of the Company’s ordinary shares on NASDAQ at a ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, today announces a clinical update and its interim results for the six months ended 30 September 2024. Clinical Updates: OK-101 Neuropathic Corneal Pain (NCP) T ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Company Overview - OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED) [1][6] - The company's ordinary shares are listed on the NASDAQ Capital Market [6] - OKYO Pharma is currently evaluating its lead program, OK-101, in Phase 2 trials for both NCP and DED [5][6] Funding and Financials - OKYO Pharma has received $1.4 million in non-dilutive funding, which will be used to advance its research and development initiatives [1][2] - The funding is strategically allocated to support the company's lead program, OK-101, particularly for the treatment of NCP [2] - This financial boost strengthens the company's ability to advance its innovative pipeline without diluting shareholder value [1][3] Product Pipeline - OK-101 is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 G-protein coupled receptor, found on immune cells, neurons, and glial cells in the eye [5] - The drug candidate has shown anti-inflammatory and pain-reducing activities in mouse models of DED and NCP [5] - OK-101 has demonstrated clear statistical significance in multiple endpoints in a Phase 2 trial for DED and is currently being evaluated in a Phase 2 trial for NCP [5][6] Market and Medical Need - NCP is a severe ocular condition without an FDA-approved therapy, currently treated with off-label topical and systemic treatments [4] - DED represents a multi-billion-dollar market, highlighting the significant commercial potential for OKYO Pharma's therapies [1] - The company is addressing critical unmet medical needs in ophthalmology, particularly for patients suffering from chronic and debilitating conditions [4][5] Leadership and Contact Information - Dr Gary S Jacob serves as the CEO of OKYO Pharma [3] - For business development and investor relations, Paul Spencer can be contacted at +44 (0)20 7495 2379 [8]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patientsOK-101 is the first IND granted by FDA to treat patients with NCP   LONDON and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat corneal neuropathic p ...